Search the Newsreel

NextCure Inc. (NXTC) Q1 2026 Earnings: EPS Beats Estimates, Stock Declines on Pre-Revenue Status - ROIC Trend Report

Shareholder Alert: Ademi LLP investigates whether NextCure, Inc. is obtaining a Fair Price for Public Shareholders

Ademi LLP is investigating NextCure (NASDAQ: NXTC) regarding potential breaches of fiduciary duty related to its transaction with Avere Therapeutics. The investigation focuses on whether the merger terms, which result in NextCure stockholders holding only 1.21% of the combined company, ensure a fair price …

NextCure announces reverse merger with privately held Avere

NextCure (NASDAQ: NXTC) announced a reverse merger with privately held Avere. This strategic transaction aims to combine NextCure's public listing with Avere's private operations to create a new entity. The merger details are expected to be elaborated upon by the companies.

NextCure (NASDAQ: NXTC) details Avere merger structure and S-4 plan

NextCure (NASDAQ: NXTC) has detailed a proposed two-step merger with Avere Therapeutics, Inc., as per an Agreement and Plan of Merger and Reorganization dated July 14, 2026. The initial step involves Neptune Merger Sub Corp. merging into Avere, making Avere a wholly-owned subsidiary of …

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of NextCure, Inc. (NASDAQ: NXTC)

Monteverde & Associates PC has launched an investigation into NextCure, Inc. (NASDAQ: NXTC) following its proposed merger with Avere Therapeutics, Inc. NextCure shareholders are expected to own approximately 1.21% of the combined company, and the firm is evaluating the fairness of this deal for …

Beltsville's NextCure merging with San Francisco startup

NextCure Inc., a Beltsville-based biotechnology company focused on cancer treatments, is merging with San Francisco startup Avere Therapeutics in an all-stock deal. NextCure had not yet brought a product to market. The acquisition includes United Therapeutics buying a biotech firm for $140M as well …

NextCure (NXTC) Slides As Avere Merger Triggers Legal Scrutiny

NextCure (NXTC) stock has slid by over 12% following news of its merger with Avere Therapeutics, triggering legal scrutiny from multiple investor-rights firms. Shareholders of NextCure are set to own only about 1.21% of the combined company, with a contingent value right for 90% …

NextCure to Merge With Avere in Stock Deal; $320 Million PIPE to Fund Combined Company

NextCure has signed a definitive merger agreement with Avere Therapeutics in a stock-for-stock transaction, which will result in Avere holders owning approximately 98% of the combined company, to be renamed Avere Therapeutics. To finance the merger, Avere secured a $320 million private placement from …

NextCure Announces Transformative All-Stock Merger With Avere

NextCure (NXTC) announced an all-stock merger with Avere Therapeutics, creating Avere Therapeutics on Nasdaq under the ticker AVRX. Avere holders and PIPE investors will own 98-99% of the new company, with NextCure shareholders receiving 1-2% plus contingent value rights from legacy asset monetization. This …